"
Team:MIT
From 2014.igem.org
| Line 17: | Line 17: | ||
<br> | <br> | ||
<table width=95% align=center> | <table width=95% align=center> | ||
| - | <tr><td><h3 style="font-size:16.5px; color:teal" align=center>< | + | <tr><td><h3 style="font-size:16.5px; color:teal" align=center><b>IMPROVING THE DIAGNOSIS AND TREATMENT OF</u></h3></td></tr> |
<tr><td><h3 style="font-size:47px; color:teal" align=center><b>ALZHEIMER'S DISEASE</b></h3></td></tr> | <tr><td><h3 style="font-size:47px; color:teal" align=center><b>ALZHEIMER'S DISEASE</b></h3></td></tr> | ||
<tr><td><h3 style="font-size:25px" align=right><br></h3></td></tr> | <tr><td><h3 style="font-size:25px" align=right><br></h3></td></tr> | ||
| Line 37: | Line 37: | ||
<tr><td><br><p style="font-size:15px" align=left><b>Alzheimer's disease is the sixth leading cause of death</b> in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association). Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable. <b>MIT iGEM 2014 is working to change this situation.</b> We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease. Using the principles of synthetic biology, we designed a system that <b>detects molecular biomarkers</b> for Alzheimer's disease and <b>alters the levels of key enzymes</b> in response. Our dynamic system combats Alzheimer's disease only when the disease is detected, providing a specific, state-sensitive treatment. In the future, an approach like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family. | <tr><td><br><p style="font-size:15px" align=left><b>Alzheimer's disease is the sixth leading cause of death</b> in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association). Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable. <b>MIT iGEM 2014 is working to change this situation.</b> We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease. Using the principles of synthetic biology, we designed a system that <b>detects molecular biomarkers</b> for Alzheimer's disease and <b>alters the levels of key enzymes</b> in response. Our dynamic system combats Alzheimer's disease only when the disease is detected, providing a specific, state-sensitive treatment. In the future, an approach like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family. | ||
<br><br> | <br><br> | ||
| - | |||
| - | |||
</table> | </table> | ||
<br><br> | <br><br> | ||
Revision as of 19:50, 17 October 2014
| Home |  Our Project
|
Lab Work
|
Outreach
|
About Us
|
Medals |
IMPROVING THE DIAGNOSIS AND TREATMENT OF | ||
ALZHEIMER'S DISEASE | ||
 |
 |
 |
NEURODEGENERATIVE |
6th LEADING CAUSE OF |
CURRENT DIAGNOSTICS AND |
Alzheimer's disease is the sixth leading cause of death in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association). Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable. MIT iGEM 2014 is working to change this situation. We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease. Using the principles of synthetic biology, we designed a system that detects molecular biomarkers for Alzheimer's disease and alters the levels of key enzymes in response. Our dynamic system combats Alzheimer's disease only when the disease is detected, providing a specific, state-sensitive treatment. In the future, an approach like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family.
|
DETECTION |
||
 NATIVE β-AMYLOID RECEPTOR |
 ENGINEERED B-CELL RECEPTOR |
 miRNA SENSORS |
RESPONSE |
DELIVERY |
 |
 |
REGULATING β-AMYLOID PRODUCTION |
DELIVERING THE CIRCUIT |
